Full-Time

Regional Clinical Trial Manager

Prilenia

Prilenia

51-200 employees

Develops pridopidine treatments for neurodegenerative diseases

No salary listed

Boston, MA, USA

Remote

Remote in the US; travel up to 50% domestically and internationally.

Category
Biology & Biotech (1)
Required Skills
Google Cloud Platform
Requirements
  • Bachelor’s degree required, preferably in science, nursing, other life sciences, biomedical discipline, or equivalent.
  • Minimum 7-10 years clinical research experience as a CRA or equivalent, such as research coordinator with of 3 years of clinical project management experience or Operations management or equivalent.
  • Demonstrated Clinical Monitoring and/or Data Management experience required.
  • Recent experience in leading the conduct of global phase 3 studies from start to completion required.
  • Experience with rare diseases required.
  • Experience with ALS or Huntington’s disease highly preferred.
  • Excellent understanding and demonstrated application of FDA guidelines, Good Clinical Practices (GCP), ICH and applicable Standard Operating Procedures.
  • Strong project management skills, stakeholder management and communication skills, including influencing executive leadership, cross-functional partners, and external collaborators.
  • Displays exceptional situational awareness in communication—adapts tone, content, and level of detail to suit the audience, from executives to technical teams. Demonstrates sound judgement in deciding what details to share or escalate.
  • Excellent problem-solving and decision-making skills.
  • Demonstrated Budget management skills required.
  • Ability to work independently, prioritize and work within a matrix team environment is essential. Ability to work across multiple projects with demonstrated ability to manage CROs (and other vendors) to meet or exceed KPIs tied to corporate goals and hold them accountable if they fall behind.
  • Proficiency with clinical research technologies and platforms (EDC, eTMF, IWRS, CTMS, etc.), plus strong skills in Microsoft Office and data analysis tools.
  • Willingness and ability to travel (domestic & international) and operate flexibly in virtual teams and global time zones. Travel up to 50% (regional).
Responsibilities
  • Oversight and management of operational activities in given regional area. Including but not limited to: multi studies regional supervision from Phase I-III, multi centers visits Ad Hoc.
  • Develop and oversee procedures for dealing with troubleshooting and problem solving.
  • Establish and monitor programs/protocols/procedures. Including but not limited to: supervision of full protocol procedures on site, joining Trainings and Visits on a routine base.
  • Support the evaluation of suitability of site personnel and facility for initial and ongoing conduct of clinical trial
  • Maintain appropriate and effective communication with vendors and other internal departments to ensure successful project completion
  • Build and sustain strong cross-functional relationships across diverse global teams; foster a culture of mutual accountability, collaboration, and innovation.
  • Communicate progress, risks, and strategic insights to executive leadership and governance committees, supporting data-driven decision-making and program advancement.
Desired Qualifications
  • Advanced degree preferred.
  • Experience with ALS or Huntington’s disease highly preferred.

Prilenia develops and commercializes medicines for brain diseases. It focuses on creating treatments for neurodegenerative conditions (like Huntington’s disease and ALS) and neurodevelopmental disorders. Its main candidate is pridopidine, a drug studied to help brain cells by activating the sigma-1 receptor (S1R), which researchers believe can help restore brain pathways impaired in these diseases. The product works by engaging S1R to support neuronal function, with the goal of slowing symptoms or progression once approved. Prilenia aims to stand out by its specific focus on S1R biology, building a pipeline of potential therapies, and bringing these treatments to patients through regulatory approval and commercialization. The company’s goal is to provide validated therapies that address urgent needs for patients and families affected by neurodegenerative and neurodevelopmental disorders, while growing its team and expanding its pipeline for future medicines.

Company Size

51-200

Company Stage

Series B

Total Funding

$115.5M

Headquarters

Herzliya, Israel

Founded

2018

Simplify Jobs

Simplify's Take

What believers are saying

  • PREVAiLS Phase 3 ALS trial enrolls first patient in 2026, advancing toward approval.
  • PROOF-HD Phase 3 trial completes last patient visit, enabling mid-2024 EU MAA submission.
  • New CFO Elisabeth Leiderman extends financial runway through Phase 3 trials and commercialization.

What critics are saying

  • PROOF-HD Phase 3 missed primary endpoint in 2023; 2026 confirmatory trials fail, terminating HD program.
  • PREVAiLS ALS Phase 3 faces recruitment failure from small, declining patient pool within 12 months.
  • Ferrer deprioritizes pridopidine post-€500M deal, blocking Prilenia's European revenue by 2028.

What makes Prilenia unique

  • Pridopidine selectively activates sigma-1 receptor to restore neuroprotective pathways in HD and ALS.
  • Prilenia holds orphan drug and FDA Fast Track designations for pridopidine in HD and ALS.
  • April 2025 Ferrer deal grants €125M upfront for Europe commercialization while retaining North America rights.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Prilenia who can refer or advise you

Benefits

Remote Work Options

Flexible Work Hours

Wellness Program

Mental Health Support

Conference Attendance Budget

Family Planning Benefits

Fertility Treatment Support

Stock Options

401(k) Retirement Plan

401(k) Company Match

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

3%
The AI Journal Ltd
Apr 28th, 2025
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets

NAARDEN, Netherlands & WALTHAM, Mass. - (BUSINESS WIRE) - Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets.

BioSpace
Sep 19th, 2024
Prilenia Appoints Rob Lauzen as Chief Financial Officer and Jason Marks as Chief Legal Officer

Prilenia appoints Rob Lauzen as Chief Financial Officer and Jason Marks as Chief Legal Officer.

Business Wire
Apr 12th, 2024
Prilenia To Present Latest Research From Its Pridopidine Programs For Huntington Disease And Als At Aan 2024

NAARDEN, Netherlands WALTHAM, Mass.--(BUSINESS WIRE)--Prilenia Therapeutics B.V., a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative diseases and neurodevelopmental disorders, today announced the presentation of the latest research from the pridopidine Huntington disease (HD) and amyotrophic lateral sclerosis (ALS) programs at the American Academy of Neurology (AAN) Annual Congress, in Denver, Colorado, April 13-18. “Pridopidine is now in pre-registration phase in HD, with a first submission planned Mid 2024i, and is also set to commence a global Phase 3 study in ALS later this year. We are making significant strides forward and this is reflected by presentation of the data at one of the most important medical congresses in the field of Neurology,” said Jina Swarz, MD. Ph.D., the recently appointed Chief Medical Officer of Prilenia. “Pridopidine is one of the most advanced investigational new drugs in HD and ALS and has shown consistent treatment benefits across independent measures that are important to patients and families. The presented data advances knowledge in the field, providing important learnings for both clinical practice and for the design of our programs going forward

Business Wire
Mar 12th, 2024
Prilenia Plans To Submit Marketing Authorization Application (Maa) In The Eu For Pridopidine In Huntington’S Disease

NAARDEN, Netherlands WALTHAM, Mass.--(BUSINESS WIRE)--Prilenia Therapeutics B.V., a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative diseases and neurodevelopmental disorders, announced its plan to submit a Marketing Authorization Application (MAA) for pridopidine for the treatment of Huntington’s disease (HD) to the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). This decision follows positive pre-submission meetings with regulatory authorities in the European Union. Submission is planned for mid-2024. “Pridopidine demonstrates consistent treatment benefits across independent measures that are important to patients and families. These measures include day-to-day function, cognition, motor and clinical progression in people living with HD. The benefits are clearly evident in those with HD who are not taking anti-dopaminergic medications (ADM),” said Dr

ALS News Today
Jan 29th, 2024
Phase 3 trial of oral pridopidine in treating ALS likely this year

On the heels of promising HEALEY-ALS Phase 2 trial data, Prilenia Therapeutics plans to launch a pivotal Phase 3 study of pridopidine, its candidate amyotrophic lateral sclerosis (ALS) treatment, in the second half of this year.